The groundbreaking success of Sildenafil undeniably transformed the drug landscape, but investing in companies primarily reliant on generic versions presents a uncertain picture. While early earnings were impressive, the expiration of patents and the appearance of discounted alternatives have eroded sales. Therefore, a thorough evaluation of curren